에스바이오메딕스

304360KOSDAQSector: Pharma & Biotech

₩17,370▼ 0.23%Market cap ₩215.1BAs of Jul 21, 2026 close · updated once daily

Grade D29.9 ptsTop 86% of 2,523 stocks

Financial strength

24.7

Growth momentum

46.4

Price attractiveness

24.0

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

24.7

How much debt does it carry relative to equity?

Debt-to-equity ratio

146.4%

✗ Below median · Top 86% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

161.0%

✗ Below median · Top 56.3% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-50.4%

✗ Below median · Top 67.7% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-93.6%

✗ Below median · Top 91.3% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

46.4

How much did revenue grow in a year?

Revenue growth (YoY)

20.5%

✓ Above median · Top 23.5% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

-53.2%

✗ Below median · Top 83.7% in sector

Sector median 3.6%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

24.0

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 59.1% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

24.81x

✗ Below median · Top 92.9% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15